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Ras oncogene expression of malignant melanoma and me-
lanocytic nevus have been immunohistochemically analyzed 
on formalin-fixed and paraffin-embedded tissues from 26 
melanomas and 24 melanocytic nevi with a monoclonal anti-
body that was generated against Harvey sarcoma virus-de-
rived ras oncogene products (p21"u). We found distinct dif-
ferences of p21 ras expressions by the type of melanoma. 
Nodular melanoma, epithelioid cell type melanoma, and 
deeply invading melanoma revealed higher reactivity with 
anti-p21 ras monoclonal antibody than the other types. The 
reactivity of melanomas appeared to correlate with the de-
gree of malignancy of the melanoma. It was also demon-
A number of monoclonal antibodies (MoAb) against melanoma have been reported since the early report of Koprowski et al [1], and most of them have been raised against cell membranes or intracellular organelles of melanoma cells. In recent years, the role of oncogenes 
in carcinogenesis has been extensively studied and MoAb against 
oncogene products have been produced to investigate the biologic 
function of oncogenes and their clinical significance [2-10]. 
Among various oncogenes, a member of the ras family has been 
intensively studied, because it was demonstrated that ras oncogenes 
have a strong transforming capacity [11]. Three human ras genes 
have been identified: Ha-(Harvey), Ki-(Kirsten) and N-ras. Ras 
gene products are known to comprise a family of proteins of molec-
ular weight 21 kD designated as p21"", and to be located on the 
cytoplasmic side of the cell membrane [12]. Furth et al [2] used rat 
cells transformed by Harvey sarcoma virus as immunogens to gener-
ate MoAb against p21''''. They found that human colonic adenocar-
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Abbreviations: 
ABC: 3-amino-9-ethyl-carbazole 
ALM: acrallentiginous melanoma 
MoAb: monoclonal antibody 
NM: nodular melanoma 
p21'''; ras oncogene products of mol wt 21 kD 
PBS: phosphate-buffered saline 
rp-12: anti-p21'" monoclonal antibody 
SSM: superficial spreading melanoma 
strated, however, that part of melanocytic nevi reacted with 
anti-p21 ras monoclonal antibody with a relatively strong in-
tensity. Melanocytic nevi with junctional activity and nevus 
cells located in the epidermis in compound nevi did not show 
the positive reaction in contrast to dermally located nevus 
cells that had relatively strong reactivity. The different p21 ras 
expression among the type of tumors may represent the state 
of tumor cells differentiation with greater expression with 
more immaturity in the melanocyte lineage. p21 ras expression 
does not appear to represent a marker of malignant transfor-
mation.] Invest Dermato193:54-59, 1989 
cinomas in general showed a similar staining intensity to that seen in 
normal mucosa. Adenomas, however, showed consistently high 
p21 ,u expression, suggesting that elevated p21 nu expression may be 
important in the development of adenomas, but that high levels 
need not to be sustained in the conversion to invasive carcinoma [3]. 
Schlom et al used a synthetic peptide reflecting positions 10-17 of 
the Ha-ras protein product from the T24 bladder carcinoma as im-
munogens, to generate MoAbs against p21'u, one of which reacted 
highly with human colon carcinomas l4,5], mammary carcinomas 
[6], bladder carcinomas [7], prostate carcinomas [8], and stomach 
adenocarcinomas [9]. p21'u expression correlated with the depth of 
carcinoma within the bowel wall, suggesting that p21'u expression 
may be a relatively rae event in colon carcinogenesis [5]. 
There have been several reports about the role of oncogenes in the 
tumorigenesis of melanoma [13-16]. Because it has been pointed 
out that the activation of ras gene by the point mutation [15] or 
enhanced transcription [16] may play some role in carcinogenesis of 
melanoma, p21'u expression of melanoma was immunohistochem-
ically examined using monoclonal anti-p21'u antibodies (rp-12). 
Preliminary studies using an immunofluorescense technique 
showed that some melanomas express p21'u on their cell mem-
branes but not melanocytic nevi [17], therefore, we used formalin-
fixed and paraffin-embedded melanomas and melanocytic nevi 
specimens for immunohistochemical analysis (avidin-biotin-perox-
idase complex method) to evaluate the role of ras oncogenes in 
melanocytic tumors. 
MATERIALS AND METHODS 
Subjects Surgically excised tissues were obtained from 26 mela-
noma patients*: 14 acrallentiginous melanoma (ALM), 7 nodular 
• Surgically excised samples were kindly supplied by Dr. K. Inoue (De-
partment of Pathology. Hokkaido University Hospital), Dr. T. Sugihara 
(Department of Plastic Surgery, Hokkaido University School of Medicine), 
and Dr. T. Aoyagi (Otaru, Hokkaido, Japan). 
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melanoma (NM), 3 superficial spreading melanoma (SSM), and 2 
metastasis. And from 24 patients with melanocytic nevus·: 6 junc-
tional, 7 compound, and 11 dermal. Malignant melanomas were 
analyzed according to Breslow's classification, TNM classification, 
and dominant cell types. 
Anti-p21- MoAb Proteins as immunogen for hybridoma prepa-
ration were produced in Escherichia coli bearing the plasmid pJLcII-
ras1 containing most of Harvey sarcoma virus ras(Ha-ras) gene. 
More than 10% of the total proteins were constituted by cII-ras 
fusion protein. Four hybridoma cell lines (rp-12, rp-28, rp-35, 
rp-38) producing anti-p21 r41 MoAb were established (NS-l 
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BALBjc mouse myeloma cells as parent cells). In the present study, 
rp-12 was used for immunohistochemical assays. Rp-12 recognize 
epitopes shared with p21 encoded by activated Ha-ras and Ki-ras 
genes derived from mice and humans and it was confirmed to be 
more specific than rp-35 and rp-38 by the preliminary study [17]. 
ImmuDoperoxidase Assays Immunohistochemical assays were 
performed using the modified methods ofHsu et al [18] as described 
previously. In brief, 4-f.Lm sections of formalin-fixed and paraffin-
embedded tissus were deparaffinized and immersed in 80% metha-
nol containing 0.3% H 20 2 to eliminate endogeneous peroxidase 
activity. The sections were rinsed in phosphate-buffered saline 
Figure 1. Immunoperoxidase staining offormalin-fixed and paraffin-embedded human tissues with MoAb rp-12 using the ABC immunoperoxidase method. 
Counterstained with hematoxylin. a: Nodular melanoma, epithelioid cell type (63-yr-old man). The brownish-red reflects the reaction of the AEC substrate 
and thus MoAb, rp-12 binding to cytoplasmic p21 nu in melanoma cells. b: Nodular melanoma, epithelioid cell type (48-yr-old woman). Melanoma cells are 
strongly positive for cytoplasmic reactivity. c: Superficial spreading melanoma, epithelioid cell types (65-yr-old man). Melanoma cells are strongly positive for 
cytoplasmic reactivity. d: Acral lentiginous melanoma, spindle cell type (77-yr-old woman). Melanoma cells are slightly positive. t : Melanocytic nevus, 
junctional type (24-yr-old man). Basal cells of epidermis are positive for cytoplasmic reactivity, but nevus cells are negative.J Melanocytic nevus, dermal type 
(34-yr-old woman). Nevus cells are positive for cytoplasmic reactivity. 
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(PBS) and incubated in normal horse serum to suppress nonspecific 
binding of proteins to some tissues, particularly collagen. Rp-12 
diluted 1 : 320 in PBS was applied for 30 min at room temperature. 
For the negative control, PBS was applied instead of MoAb. After 
washing in PBS, the sections were incubated with biotinylated 
horse anti-mouse IgM (Vector Laboratories, Inc., Burlingame, CA) 
for 30 min, and then treated with avidin dehydrogenase and biotin-
ylated horseradish peroxidase H complex for 30 min. After another 
rinse in PBS, the sections were treated with 3-amino-9-ethyl-carba-
zole (AEe) and were counterstained with hematoxylin. 
Immunohistochemical Evaluation We used a modification of 
the method by Thor et al [5]. Each section was evaluated for the 
presence of AEC precipitate indicative of primary MoAb binding 
under a light microscope using the following scoring system: (-) 
negative; (+) clearly positive; (++) strongly positive. The approxi-
mate percentage of cells expressing p21"" in melanoma tissues was 
scored according to the number of positive melanoma cells divided 
by the total number of melanoma cells. Results were statistically 
analyzed by the Chi-square test. 
RESULTS 
Immunoreactive p21"" was demonstrated as brownish-red granules 
within the cytoplasm of melanoma and nevus cells (Fig 1). These 
AEC precipitates were easily differentiated from melanin granules, 
and no AEC precipitates were observed in the control tissues. Be-
sides melanoma and nevus cells, basal cells of the epidermis and 
eccrine glands revealed a positive reaction. The results of26 malig-
nant melanomas and 24 melanocytic nevi were analyzed as follows. 
Malignant Melanoma 
Type oj Melanoma Among the types of malignant melanomas, dis-
tinctive differences both in staining intensity and in the percentage 
of positive cells were demonstrated (Table I, Fig 2). In 14 cases of 
ALM, 1 was strongly positive,S were clearly positive, and 8 were 
negative. In 7 cases ofNM, 4 were strongly positive, 2 were clearly 
positive, and 1 was negative. This difference was statistically signifi-
cant in which NM cells were more intensely stained than in ALM 
cells (X2 = 8.9, P < 0.02). In 3 cases of SSM and 2 cases of metas-
tasis, all cases were clearly positive. The percentage of positive cells 
by rp-12 in NM was higher than in ALM or SSM. 
Dominant Cell Type Melanoma cases were histopathologically clas-
sified by their cytologic appearances into large epithelioid cell type, 
spindle cell type, and small cell type according to Lund and Kraus 
[19] (Table II, Fig 3). Usually, different cell types were admixed in 
the same section. A predominant cell type (more than 50% in the 
tissue) was used for the present analysis. It was also evident that 
reactivity of rp-12 was different among cell types. Of 16 cases of 
epithelioid cell type, 4 were strongly positive, 10 were clearly posi-
tive, and 2 were negative. And in 8 cases of spindle cell type, 1 was 
strongly positive, 1 was clearly positive, and 6 were negative. It was 
statistically significant that epithelioid melanoma cells were more 
intensely stained than spindle cells (X2 = 9.6, P < 0.01). In 2 cases 
of small cell type, one was clearly positive and another was negative. 
Table I. Immunoperoxidase Staining of Malignant Melanoma 
with MoAb rp-12 (Type of Melanoma) 
Number 
of Cases ++ + 
ALM 14 1 (7%) 5 (36%) 8 (57%) 
NM 7 4 (57%) 2 (29%) 1 (14%) 
SSM 3 o (0%) 3 (100%) o (0%) 
Metastasis 2 o (0%) 2 (100%) 0(0%) 
Total 26 5 (19%) 12 (46%) 9 (35%) 
ALM = acral lentiginous melanoma; NM - nodular melanoma; SSM - sup<:rficial 
spreading melanoma. 
Intensity score for irnmunoperoxidase staining: ++. strongly positive; +. clearly 
positive; - . negative . 
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Figure 2. Percentage of reactivity of MoAb rp-12 with formalin-fixed and 
paraffin-embedded malignant melanoma tissues using immunohistochemi-
cal assay. Each symbol represents a different individual. The percentage of 
positive cells denotes the number of melanoma cells scoring p21"" positive 
divided by the total number of melanoma cells X 100 in each lesion (type of 
melanoma). 
The percentage of positive cells in epithelioid cell type melanoma 
was also significantly higher than those in spindle cell type (X2 = 
9.8, P = <0.05). 
TNM Classification (stage) The reactivity of rp-12 was compared by 
the stage o(TNM classification. Most of the cases were stage I and 
stage II melanomas. We did not find any difference in staining 
intensity or the percentage of positive cells in each stage. 
Breslow's Classification The group of more than 1.5-mm thickness 
melanomas was more strongly stained than the group of less than 
1.5 mm thickness (X2 = 5.5, p < 0.1) (Table III, Fig 4). The per-
centage of positive cells was also higher in the group more than 
t.5 mm in thickness. 
M elanocytic Nevi Nevus cells in 13 of24 cases (55%) of melano-
cytic nevi revealed a positive reaction with rp-12, however, a dis-
tinctive difference was pres~nt in the reactivity among the types of 
nevi (Table IV, Fig 5). In 6 cases of junctional type, all cases were 
negative with rp-12. In 7 cases of compound type, t was strongly 
Table II. Immunoperoxidase Staining of Malignant Melanoma 
with MoAb rp-12 (Dominant Cell Type) 
Dominant Number 
Cell Type of Cases ++ + 
Epithelioid Cell Type 16 4 (25%) 10 (63%) 2 (12%) 
Spindle Cell Type 8 1 (13%) 1 (13%) 6 (74%) 
Small Cell Type 2 0(0%) 1 (50%) 1 (50%) 
Intensity score for immunoperoxidase staining: ++. strongly positive; +. clearly 
positiye~ -, negative. 
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Figure 3. Percentage of reactivity of MoAb rp-12 with malignant mela-
noma (dominant cell type) . 
positive, 3 were clearly positive, and 3 were negative for cells lo-
cated in the dermis. Epidermal nests in the compound nevi did not 
react with rp- 12 as well as those in junctional nevi. In 11 cases of 
dermal type, 3 were strongly positive, 6 were clearly positive, and 2 
were negative. Therefore, nevus cells were significantly less stained 
injunctional than in the other two types (X2 = 9.5, P < 0.01). The 
percentage of positive cells injunctional nevi was also significantly 
less than in the other two types (X2 = 10.4, P < 0.02) . 
DISCUSSION 
Several MoAb directed against p21 "" have been generated and iden-
tified with reactivity to many neoplastic tissues, nonneoplastic tis-
sues, and normal tissues [2 - 10]. We used an immunohistochemical 
assay that employed a MoAb(rp-12) generated against p21"" to in-
vestigate the relationship between p21'" expression and malignant 
transformation of melanocytes. We have previously shown that 
lung cancer tissues of all the different histologic types were strongly 
reactive with rp-35 and those of well or moderately differentiated 
adenocarcinoma had high reactivity with rp-28. These cancer tis-
sues showed membrane-associated staining, but bronchial epithelial 
and glandular tissues and macrophages in pleural effusion showed 
Table m. Immunoperoxidase Staining of Malignant Melanoma 
with MoAb rp-12 (Breslow's Classification) 
Number 
of Cases ++ + 
<0.75 mm 4 0(0%) 1 (25%) 3 (75%) 
0.75 - 1.5 mm 3 0(0%) 1 (33%) 2 (67%) 
1.5 - 3.0 mm 5 1 (20%) 3 (60%) 1 (20%) 
> 3.0 mm 12 4 (33%) 5 (42%) 3 (25%) 
In~ensity score for immunoperoxidase staining: ++, strongly positive; +, clearly 
posItive; - . negative. 
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Figure 4. Percentage of reactivity of MoAb rp-12 with malignant mela-
noma (Breslow's classification) . 
cytoplasmic staining [20]. And also, rp-28 highly reacted with gas-
tric cancers. Cell membrane and cytoplasm of malig-
nant cells showed positive immunoreactivity in gastric cancers, 
but p21 ,., was observed in cytoplasm of positive cells in benign 
tissues [21] . 
In the present study, we could not identify any differences in the 
pattern of cellular localization of immunoreactive p21 ,., detected by 
AEC precipitates. Both melanoma cells and nevus cells had the 
positive reactivity in their cytoplasm. Although p21 ros is considered 
a membrane-associated protein, the immunohistochemical presen-
tation of p21 ,., may depend on the fixation method, more easily 
demonstrated in formalin-fixed and paraffin-embedded tissues 
compared with freshly frozen sections. 
Because an activated Ha-ras gene was detected from cultured 
human melanoma cells by a DNA transfection method to 
NIH/3T3 cells [15), the role of ras genes may be important in 
melanoma oncogenesis. An interesting result in the present study 
was that both staining intensity and number of positive cells corre-
lated with the tumor type, the cellular type, and the depth of inva-
sion. The more malignant the melanomas were, the more inten-
sively melanoma cells reacted with anti-p21'4SMoAb . Nodular 
Table IV. Immunoperoxidase Staining of Melanocytic Nevus 
with MoAb rp-12 
Number 
of Cases ++ + 
Junctional 6 0(0%) 0(0%) 6 (100%) 
Compound 7 1 (14%) 3 (43%) 3 (43%) 
Dermal 11 3 (27%) 6 (55%) 2 (18%) 
Total 24 4 (17%) 9 (38%) 11 (45%) 
Intensity score for immunoperoxid ... staining: ++, strongly positive; +. clearly 
positive: -. negative. 
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Figure S. Percentage of reactivity of MoAb rp-12 with melanocytic nevus 
tissues. The percentage of positive cells denotes the number of nevus cells 
scoring p21ras positive divided by the total number of nevus cells X 100 in 
each lesion. 
melanoma is composed largely of an epithelioid type of cells, ALM 
tend$ to show a predominance of spindle-shaped cells [22]; NM has 
poorer prognosis than ALM and the prognosis correlates with 
tumor thickness [22,23]. Also it has been suggested that NM repre-
sents the end stage of all types of melanoma instead of a distinctive 
entity [24). From these findings, it may be hypothesized that ras 
oncogene expression is involved in a relatively late event in mela-
noma oncogenesis similar to colon carcinomas reported by Thor et 
al [5]. Because melanocytic nevi showed high reactivity with rp-12, 
however, other mechanisms must also be proposed for the expres-
sion of p21'" in these melanocytic tumors. 
The anatomic location of cells in melanocytic nevi does not ap-
pear to influence their proliferative capacity but has a marked effect 
on their differentiation. Although cell kinetic studies of melanocy-
tic nevus are limited, autoradiographs prepared from incubated 
nevus tissues showed that repricative activities were similar for all 
anatomic areas within melanocytic nevus [25] . The nevus cells dif-
fered from one another by anatomic site irt cellular structure, mela-
nin content, tyrosinase activity, and cholinesterase activity [26,27]' 
Nevus cells in the epidermis possess melanin granules and dendritic 
processes indistinguishable from dendrites of epidermal melano-
cytes. Nevus cells in the papillary dermis commonly resemble 
epithelioid cells, aggregate in nests, demonstrate abundant tyrosin-
ase activity and negative cholinesterase activity, and contain mela-
nin. In contrast, nevus cells in the deep dermis may resemble fibro-
blasts or Schwann cells, lie in single array, demonstrate minimal 
(but definite) tyrosinase activity, and usually do not contain mela-
nin. Thus, nevus cells are homogeneous regarding proliferation but 
heterogeneous in their degree of differentiation comparable witb 
melanocyte differentiation from melanoblasts to mature melano-
cytes. The different expressions of p21 , .. by the location of nevus 
cells may reflect this heterogeneity of nevus cells. 
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It may also be hypotbesized that the heterogeneous p21'" expres-
sions in melanoma by various types represent the differentiation 
status of melanoma cells. Epithelioid cells usually present in NM are 
comparable to immature melanoblasts and possess abundant p21'''. 
Spindle or dendritic cells in ALM, on the other band, resemble 
mature melanocytes and possess less p21'''. Similar findings were 
demonstrated by a study using anti-melanoma MoAb in which the 
expressions of cell surface antigen correlated with the state of differ-
entiation both in the evolution of melanocyte and in the type of 
melanoma [28]. 
It is well known that oncogenes present in normal cells (protoon-
cogene) play an essential role in cellular functions, especially regu-
lating cell proliferation or differentiation, or both, in addition to 
their role in carcinogenesis. p21'" has been shown to have partial 
bomology to GTP-binding protein [29] and have GTPase activity 
[30], suggesting the function of p21'" in the modulation of signals 
from membrane receptors into biologic cell responses. It has been 
demonstrated that the expressions of ras oncogenes are enhanced in 
normal tissues, such as regenerating liver [31] and fetal and neonatal 
development [32,33]. Some investigators have suggested that ras 
oncogenes are involved in cellular [34,35] and organ [36] differen-
tiation as well. Although p21ras expression in normal melanocyte 
lineage has not been studied yet, it may be suggested that p21'" is 
expressed in nevus cells and melanoma cells that have similar char-
acteristics, i.e. , less melanin production,less tyrosinase activity, and 
less dendritic processes. It is more likely the expression of p21'" is a 
marker of the undifferentiated stage of melanocyte lineage (evolu-
tion) than it is a marker of malignant transformation. The present 
immunohistochemical study could not identify the role of ras onco-
genes in the tumorigenesis of melanoma. It may be hypothesized, 
however, that malignant transformation is evoked in high fre-
quency through ras gene activation because immature melanocytes 
have active expressions of ras genes. 
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